AR002720A1 - Proceso para preparar una composición oral sólida de olanzapina con subrecubrimiento de polímero y recubrimiento coloreado - Google Patents

Proceso para preparar una composición oral sólida de olanzapina con subrecubrimiento de polímero y recubrimiento coloreado

Info

Publication number
AR002720A1
AR002720A1 ARP960101877A AR10187796A AR002720A1 AR 002720 A1 AR002720 A1 AR 002720A1 AR P960101877 A ARP960101877 A AR P960101877A AR 10187796 A AR10187796 A AR 10187796A AR 002720 A1 AR002720 A1 AR 002720A1
Authority
AR
Argentina
Prior art keywords
solid oral
preparing
olanzapine
oral composition
colored coating
Prior art date
Application number
ARP960101877A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23624847&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR002720(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR002720A1 publication Critical patent/AR002720A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La invención proporciona un procedimiento para preparar formulaciones orales sólidas recubiertas farmacéuticamente apropiadas y aceptables deolanzepina de fórmula (I), mediante la granulación en húmedo (acuosa) bajo condiciones de elevadocizallamiento y secado en lecho fluido.De preferenciacorresponde, a la poliforma Forma II pura que tiene el patrón de difracción de RX (en polvo) detallado en la descripción.
ARP960101877A 1995-03-24 1996-03-22 Proceso para preparar una composición oral sólida de olanzapina con subrecubrimiento de polímero y recubrimiento coloreado AR002720A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41046595A 1995-03-24 1995-03-24

Publications (1)

Publication Number Publication Date
AR002720A1 true AR002720A1 (es) 1998-04-29

Family

ID=23624847

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP960101877A AR002720A1 (es) 1995-03-24 1996-03-22 Proceso para preparar una composición oral sólida de olanzapina con subrecubrimiento de polímero y recubrimiento coloreado
AR33587496A AR001405A1 (es) 1995-03-24 1996-03-22 Formulación oral de 2-metil-tieno-beno-diacepina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
AR33587496A AR001405A1 (es) 1995-03-24 1996-03-22 Formulación oral de 2-metil-tieno-beno-diacepina.

Country Status (46)

Country Link
US (4) US5919485A (es)
EP (2) EP1093815B1 (es)
JP (1) JPH11502848A (es)
KR (1) KR100408172B1 (es)
CN (1) CN1178662C (es)
AP (1) AP679A (es)
AR (2) AR002720A1 (es)
AT (3) ATE206924T1 (es)
AU (1) AU696601B2 (es)
BG (1) BG62594B1 (es)
BR (1) BR9607791A (es)
CA (1) CA2216372C (es)
CH (1) CH691217A5 (es)
CO (1) CO4700474A1 (es)
CR (1) CR5278A (es)
CZ (1) CZ296007B6 (es)
DE (3) DE69634053T2 (es)
DK (3) DK0733367T3 (es)
EA (1) EA000938B1 (es)
EE (1) EE03551B1 (es)
EG (1) EG24077A (es)
ES (2) ES2232379T3 (es)
FI (1) FI973749A (es)
GB (1) GB2313783B (es)
HU (1) HU225269B1 (es)
IL (1) IL117611A (es)
IS (1) IS1903B (es)
LT (1) LT4350B (es)
LU (1) LU90115B1 (es)
LV (1) LV11983B (es)
MY (1) MY113440A (es)
NO (1) NO320388B1 (es)
NZ (1) NZ306111A (es)
OA (1) OA10511A (es)
PE (1) PE44997A1 (es)
PL (1) PL188316B1 (es)
PT (2) PT1093815E (es)
RO (1) RO118370B1 (es)
SE (1) SE9703206L (es)
SI (3) SI0733367T1 (es)
SK (1) SK283745B6 (es)
TR (1) TR199701018T1 (es)
TW (1) TW426526B (es)
UA (1) UA44766C2 (es)
WO (1) WO1996029995A1 (es)
ZA (1) ZA962338B (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
ID21762A (id) * 1996-09-24 1999-07-22 Lilly Co Eli Formulasi partikel bersaput
US8563522B2 (en) * 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US20020035071A1 (en) * 1997-07-08 2002-03-21 Josef Pitha Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites
US20060116330A1 (en) * 1997-07-08 2006-06-01 The Iams Company Methods of mimicking the metabolic effects of caloric restriction by administration of mannoheptulose
US6617321B2 (en) 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
US7022698B2 (en) 1999-12-28 2006-04-04 U & I Pharmaceuticals, Ltd. Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
NZ519926A (en) * 1999-12-28 2004-02-27 Cipla Ltd New polymorphic forms of olanzapine
US6348458B1 (en) 1999-12-28 2002-02-19 U & I Pharmaceuticals Ltd. Polymorphic forms of olanzapine
US6740753B2 (en) 2001-01-04 2004-05-25 Geneva Pharmaceuticals, Inc. Olanzapine crystal modification
US20030072731A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing starch or dextrin
US20030072729A1 (en) * 2001-05-15 2003-04-17 Christopher Szymczak Simethicone as weight gain enhancer
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
US8309118B2 (en) 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
GB0203061D0 (en) * 2002-02-08 2002-03-27 Novartis Ag Organic compounds
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
WO2003086361A1 (en) * 2002-04-18 2003-10-23 Dr. Reddy's Laboratories Ltd. Rapidly dispersing solid oral compositions
ATE500258T1 (de) 2002-05-31 2011-03-15 Sandoz Ag Verfahren zur herstellung von olanzapin form i
SI21270A (sl) * 2002-07-15 2004-02-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Kristalne oblike olanzapina in postopki za njihovo pripravo
US7029112B2 (en) 2002-08-05 2006-04-18 Mars, Incorporated Ink-jet printing on surface modified edibles and products made
US8168170B2 (en) * 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
PL202856B1 (pl) * 2002-12-20 2009-07-31 Adamed Spo & Lstrok Ka Z Ogran Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny
WO2005009407A2 (en) * 2003-07-29 2005-02-03 Ranbaxy Laboratories Limited Oral pharmaceutical formulations of olanzapine
US20050112196A1 (en) * 2003-10-07 2005-05-26 Jianbo Xie Rapidly disintegrating formulation
CA2546200A1 (en) * 2003-11-18 2005-06-02 3M Innovative Properties Company Olanzapine containing transdermal drug delivery compositions
US8877178B2 (en) * 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050152884A1 (en) * 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US8894991B2 (en) * 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US20050158294A1 (en) * 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US7785635B1 (en) * 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
ES2253091B1 (es) * 2004-07-27 2007-02-01 Inke, S.A. Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
WO2006073886A1 (en) 2005-01-05 2006-07-13 Eli Lilly And Company Olanzapine pamoate dihydrate
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
PL385455A1 (pl) * 2005-04-22 2008-11-24 Teva Pharmaceuticals Usa,Inc. Doustna rozpadająca się farmaceutyczna tabletka preparatów olanzapiny
EP1885383B1 (en) * 2005-05-31 2016-09-21 IAMS Europe B.V. Feline probiotic bifidobacteria
AR052472A1 (es) * 2005-05-31 2007-03-21 Iams Company Lactobacilos probioticos para felinos
US20070014847A1 (en) * 2005-07-05 2007-01-18 Ahmed Salah U Coated capsules and methods of making and using the same
KR20080039876A (ko) * 2005-07-22 2008-05-07 미리어드 제네틱스, 인크. 높은 약물 충진 제형 및 투여형
WO2007049304A2 (en) * 2005-10-27 2007-05-03 Jubilant Organosys Limited Stable coated pharmaceutical formulation of olanzapine and process for preparing the same
GB0522473D0 (en) * 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
GB0522474D0 (en) 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
ES2279715B1 (es) * 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
US7834176B2 (en) 2006-01-26 2010-11-16 Sandoz Ag Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
WO2007134845A2 (en) * 2006-05-18 2007-11-29 Synthon B.V. Olanzapine pharmaceutical composition
CN101484141A (zh) * 2006-07-05 2009-07-15 比利姆制药工业和贸易公司 包含抗氧化剂的稳定的奥氮平制剂
CL2007002807A1 (es) * 2006-09-29 2008-04-11 Synthon Bv Composicion farmaceutica en estado solido que comprende olanzapina o una sal farmaceuticamente aceptable de la misma y lactosa anhidra; tableta farmaceutica oral; procedimiento de preparacion de dicha tableta, util en el tratamiento de la esquizofren
WO2008093303A2 (en) 2007-02-01 2008-08-07 The Iams Company Method for decreasing inflammation and stress in a mammal using glucose antimetaboltes, avocado or avocado extracts
CN101983055B (zh) * 2008-01-31 2013-05-08 杏林制药株式会社 以咪达那新为有效成分的口腔内速崩片的制造方法
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
WO2010111560A1 (en) * 2009-03-25 2010-09-30 Pax Streamline, Inc. Supersonic cooling system
US8505322B2 (en) * 2009-03-25 2013-08-13 Pax Scientific, Inc. Battery cooling
US20110048048A1 (en) * 2009-03-25 2011-03-03 Thomas Gielda Personal Cooling System
US20110051549A1 (en) * 2009-07-25 2011-03-03 Kristian Debus Nucleation Ring for a Central Insert
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
US8365540B2 (en) * 2009-09-04 2013-02-05 Pax Scientific, Inc. System and method for heat transfer
WO2012153347A2 (en) 2011-05-04 2012-11-15 Zentiva K.S. Oral pharmaceutical composition of olanzapine form 1
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9517212B1 (en) * 2012-11-15 2016-12-13 Chandra Zaveri Medicated adhesive pad arrangement
CN103919782B (zh) * 2013-01-15 2016-12-28 天津药物研究院有限公司 一种含有奥氮平的药物组合物及其制备方法
DK3043778T3 (da) * 2013-09-13 2017-11-27 Bayer Pharma AG Farmaceutiske sammensætninger, der indeholder refametinib
CN107007559B (zh) * 2017-04-21 2020-05-15 浙江京新药业股份有限公司 一种稳定的口服药物组合物及其制备方法
WO2018222922A1 (en) * 2017-06-02 2018-12-06 Xeris Pharmaceuticals, Inc. Precipitation resistant small molecule drug formulations
CN113143878A (zh) * 2021-03-19 2021-07-23 杭州新诺华医药有限公司 奥氮平组合物及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172831A (en) * 1974-11-26 1979-10-30 Lilly Industries Limited Thieno-benzodiazepines
US4115568A (en) * 1974-11-26 1978-09-19 Lilly Industries Limited Thieno[3,2-b]-[1,5]benzodiazepines
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US4820522A (en) * 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
ZA922777B (en) * 1991-04-29 1993-10-15 Lilly Co Eli Pharmaceutical formulation containing dirithromycin
JPH05194225A (ja) * 1991-11-07 1993-08-03 Yoshitomi Pharmaceut Ind Ltd 安定化された抗潰瘍剤含有製剤
ATE198891T1 (de) * 1992-05-29 2001-02-15 Lilly Co Eli Thienobenzodiazepinderivate zur behandlung von störungen des zentralnervensystems
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
US5696115A (en) * 1995-04-21 1997-12-09 Eli Lilly And Company Method for treating nicotine withdrawal

Also Published As

Publication number Publication date
LT97149A (en) 1998-01-26
JPH11502848A (ja) 1999-03-09
DE19681287T1 (de) 1998-03-19
EP1093815B1 (en) 2004-12-15
MX9707186A (es) 1997-11-29
DK109097A (da) 1997-11-12
EP0733367B1 (en) 2001-10-17
RO118370B1 (ro) 2003-05-30
US5919485A (en) 1999-07-06
TW426526B (en) 2001-03-21
ES2232379T3 (es) 2005-06-01
CO4700474A1 (es) 1998-12-29
EA199700260A1 (ru) 1998-02-26
AU696601B2 (en) 1998-09-17
CN1179102A (zh) 1998-04-15
TR199701018T1 (xx) 1998-01-21
US7229643B2 (en) 2007-06-12
US6190698B1 (en) 2001-02-20
NZ306111A (en) 1999-02-25
SI0733367T1 (en) 2002-06-30
FI973749A0 (fi) 1997-09-22
PE44997A1 (es) 1997-10-23
LU90115B1 (fr) 1997-09-10
HUP9800410A2 (hu) 1998-07-28
PT733367E (pt) 2002-03-28
DK173323B1 (da) 2000-07-24
LV11983B (en) 1998-07-20
LT4350B (lt) 1998-05-25
NO974363L (no) 1997-11-17
CH691217A5 (de) 2001-05-31
BG101901A (en) 1998-10-30
AT405606B (de) 1999-10-25
DE69615887D1 (de) 2001-11-22
GB9719817D0 (en) 1997-11-19
HU225269B1 (en) 2006-08-28
BR9607791A (pt) 1998-07-07
OA10511A (en) 2002-04-24
SE9703206D0 (sv) 1997-09-05
AU5428096A (en) 1996-10-16
PL322579A1 (en) 1998-02-02
SK128297A3 (en) 1998-03-04
IS1903B (is) 2003-11-20
GB2313783B (en) 1998-11-18
SI9620041A (sl) 1998-06-30
EE9700328A (et) 1998-06-15
DK0733367T3 (da) 2001-11-26
PL188316B1 (pl) 2005-01-31
CZ300197A3 (en) 1997-12-17
US20010018071A1 (en) 2001-08-30
HUP9800410A3 (en) 2000-01-28
BG62594B1 (bg) 2000-03-31
LV11983A (lv) 1998-03-20
DE69634053T2 (de) 2005-12-22
US20050085462A1 (en) 2005-04-21
CN1178662C (zh) 2004-12-08
IS4565A (is) 1997-09-22
ES2164837T3 (es) 2002-03-01
MY113440A (en) 2002-02-28
CR5278A (es) 1996-07-04
NO974363D0 (no) 1997-09-22
UA44766C2 (uk) 2002-03-15
CZ296007B6 (cs) 2005-12-14
SI1093815T1 (en) 2005-06-30
NO320388B1 (no) 2005-11-28
IL117611A0 (en) 1996-07-23
ZA962338B (en) 1997-09-22
AP679A (en) 1998-09-28
EG24077A (en) 2008-05-11
KR100408172B1 (ko) 2004-02-18
SK283745B6 (sk) 2003-12-02
SE9703206L (sv) 1997-09-05
AR001405A1 (es) 1997-10-22
PT1093815E (pt) 2005-03-31
DE69634053D1 (de) 2005-01-20
AP9701064A0 (en) 1997-10-31
ATE284695T1 (de) 2005-01-15
EP0733367A1 (en) 1996-09-25
KR19980703189A (ko) 1998-10-15
ATA902296A (de) 1999-02-15
CA2216372A1 (en) 1996-10-03
EA000938B1 (ru) 2000-06-26
US6780433B2 (en) 2004-08-24
EE03551B1 (et) 2001-12-17
DK1093815T3 (da) 2005-04-25
CA2216372C (en) 2007-11-20
FI973749A (fi) 1997-09-22
WO1996029995A1 (en) 1996-10-03
GB2313783A (en) 1997-12-10
ATE206924T1 (de) 2001-11-15
IL117611A (en) 2002-05-23
EP1093815A1 (en) 2001-04-25
DE69615887T2 (de) 2002-04-11

Similar Documents

Publication Publication Date Title
AR002720A1 (es) Proceso para preparar una composición oral sólida de olanzapina con subrecubrimiento de polímero y recubrimiento coloreado
AR048457A2 (es) Proceso para formar una composicion farmaceutica de topiramato
AR012717A1 (es) Trihidrato de la sal de magnesio de s-omeprazol, proceso para su preparacion, composicion farmaceutica, y uso de dicho trihidrato para la fabricacion de medicamentos.
EA200300999A1 (ru) Хронотерапевтические дозированные формы
HUP0202186A3 (en) Benzimidazolone derivatives, process for their preparation, pharmaceutical compositions containing them and their use as phosphodiesterase inhibitors for producing pharmaceutical compositions
NO20000284D0 (no) Tanninsyre-polymerblandinger for kontrollert frigivelse av farmasoeytiske midler, saerlig i munnhulen
BR0201904A (pt) Composições de revestimento por imersão contendo éteres de celulose
AR012125A1 (es) UNA SAL DE UN COMPUESTO DERIVADO DEL ÁCIDO NAFTIRIDINA CARBOXíLICO , SU USO PARA LA FABRICACIoN DE UN MEDICAMENTO , PROCEDIMIENTO PARA PREPARARLA Y UNA COMPOSICIoN FARMACÉUTICA QUE LO COMPRENDE
AR025052A1 (es) Derivados de 2-dialquilaminoalquilbifenilo sustituidos, procedimiento para su preparacion, medicamentos que contienen estos compuestos y el uso de estoscompuestos para la preparacion de medicamentos.
BR0013311A (pt) Derivados substituìdos de 1,5-dihidropirrol-2-ona eficazes como antagonistas de receptores nmda para o tratamento de estados de dor
HUP0401747A3 (en) Piridazine derivatives of hydrazono-malonitriles, their use, process for preparation of the compounds and pharmaceutical compositions containing the compounds
DE69715009D1 (de) Substituierte thiazolidinedione derivate, ihre herstellung und pharmazeutische zusammensetzungen, die sie enthalten
HUP0202233A3 (en) Derivatives and analogues of galanthamin, their use, pharmaceutical compositions containing them and process for the preparation of them
HUP9802393A3 (en) Benzothiazolone derivatives, their use, pharmaceutical compositions containing them, process for the preparation thereof and intermediates
NO20033318L (no) 2H-1-benzopyranderivater, fremgangsmåte ved fremstilling samt farmasöytiskesammensetninger derav
HK1087126A1 (en) Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction
DK1118610T3 (da) Benzensulfonamid-derivater, fremgangsmåde til fremstilling heraf samt farmaceutiske sammensætninger indeholdende derivaterne
AU1373097A (en) New phospholipid derivatives of phosphonocarboxylic acids, the production thereof as well as their use as antiviral pharmaceutical agents
MXPA03001610A (es) Derivados de acido oxazolil-arilpropionico y su uso como agonistas de los receptores activados por proliferadores de peroxisomas.
BR0114380A (pt) Derivados-1-aminobutan-3-ol-substituìdos
HUP9602640A2 (en) Substituted benzoyl-guanidine derivatives, process for producing them, pharmaceutical compositions containing them and the use of the compds.
NO993912D0 (no) Fremgangsmåte for fremstilling av eprosartan
HUP0200343A3 (en) Phenylalaninol derivatives, process for their preparation, pharmaceutical compositions containing them and their use
AR012601A1 (es) Derivados de amidina, formulaciones farmaceuticas que los contiene, uso de dichos derivados en la preparacion de medicamentos y proceso para lapreparacion de dichos derivados
NO993913D0 (no) Fremgangsmåte for fremstilling av eprosartan

Legal Events

Date Code Title Description
FC Refusal